
Work Here?
Helaina creates advanced nutritional supplements by using a platform that replicates functional human proteins so they can be taken as nutrients. Its flagship product, Effera™, is a replicated version of Human Lactoferrin, a protein found in the body that supports gut health, iron use, and immune function. The protein-based supplement is intended for health-conscious consumers who want science-backed, high-quality ingredients beyond basic nutrition. Unlike typical supplement companies that source standard nutrients, Helaina focuses on producing bioactive proteins as dietary ingredients through its proprietary technology. The company's goal is to improve overall health and vitality by making these human-like proteins available as accessible supplements.
Industries
Food & Agriculture
Biotechnology
Healthcare
Consumer Goods
Company Size
11-50
Company Stage
Series B
Total Funding
$69.6M
Headquarters
New York City, New York
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$69.6M
Above
Industry Average
Funded Over
4 Rounds
Industry standards
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
401(k) Company Match
Unlimited Paid Time Off
Paid Parental Leave
Childcare Support
Commuter Benefits
Leadership Development coaching through BetterUp
Startups are emerging globally to mass-produce the rare protein human lactoferrin using microbial precision fermentation. In the U.S., several consumer products using precision-fermented human lactoferrin have already launched. Companies like Australia's Eclipse Ingredients, U.S.-based Helaina, and Portugal's PFx Biotech are advancing with funding in the millions to expand the human-derived lactoferrin market.
Helaina, the biotechnology company transforming nutrition with human equivalent bioactive proteins, announced today it has raised $45 million in Serie
The biotech company is writing the safety playbook on novel bioactive proteins and to help with this, Helaina hired a nutritional sciences and regulatory affairs veteran, Ross Peterson, PhD, Helaina's new Director of Regulatory Affairs.
After achieving a large-scale manufacturing milestone, bioactive protein company Helaina announces that its first high-value ingredient —animal-free lactoferrin — is ready for commercialization to create consumer products focused on immune health. . Founded in 2019 in New York City, Helaina has raised more than $25 million from leading investors. Helaina is a member of the Precision Fermentation Alliance, a new trade organization formed to promote precision fermentation as a solution for a more resilient and sustainable food system. . A protein found in breast milk, lactoferrin is known for improved nutrient absorption, cognitive support, and antimicrobial defense. Helaina says it improves infant formula and functional foods, such as nutritional bars or supplements
While investor sentiment may have soured on alternative proteins, the recent Future Food-Tech summit in San Francisco attracted a record number of foodtech startups showcasing everything from a chatbot steeped in the latest food trends to lactoferrin from precision fermentation. AFN caught up with a selection of exhibitors at the event, which brought together 1,700 entrepreneurs, investors, and food industry professionals from 52 countries. TasteGPT… ‘like having a personalized, concierge market research assistant that’s always available’
Find jobs on Simplify and start your career today
Industries
Food & Agriculture
Biotechnology
Healthcare
Consumer Goods
Company Size
11-50
Company Stage
Series B
Total Funding
$69.6M
Headquarters
New York City, New York
Founded
2019
Find jobs on Simplify and start your career today